BullBD Old Apps Site
Home
Details Chart Today news Share news Top gainer Top Looser Upcoming events
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0 1 2 3 4 5 6 7 8 9 All
Bank Cement Ceramics Sector Corporate Bond Engineering Financial Institutions Food & Allied Fuel & Power IT Sector Insurance Jute Life Insurance Miscellaneous Mutual Funds Paper & Printing Pharmaceuticals & Chemicals Services & Real Estate Tannery Industries Telecommunication Textile Travel & Leisure All
  • Details
  • Chart
  • News

BXPHARMA

All Eps Dividend Board Agm Q1 Q2 Q3

BXPHARMA 24-Jan-2021

(Cont. News of BXPHARMA): The Proposed Transaction is for a total of 1,963,241 shares, representing approximately 54.6 Percent of Sanofi Bangladesh's total share capital. Beximco Pharma was selected as the preferred bidder in a competitive process. The remaining 45.4 percent shares in Sanofi Bangladesh is owned by the Government of Bangladesh through Bangladesh Chemical Industries Corporation (approximately 20 percent) and the Ministry of Industries (approximately 25.4 percent). (Cont.2)

BXPHARMA 24-Jan-2021

The Company has informed that Board of Directors of the company in their meeting held on January 21, 2021 at 2.30 PM decided to enter into a binding commitment with Sanofi Group regarding the acquisition of a majority stake in Sanofi Bangladesh Limited for a base-price consideration of circa Pound 35.5 million, to be adjusted as set out below (the Proposed Transaction). The Proposed Transaction is subject to approval by the Bangladesh Bank and completing the Share Purchase Agreement. (Cont.1)

BXPHARMA 18-Jan-2021

The Company has informed that it has disbursed the cash dividend for the year ended on June 30, 2020 to the respective shareholders' Bank Accounts through BEFTN system.

BXPHARMA 18-Jan-2021

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 27, 2021 at 3:30 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended on December 31, 2020.

BXPHARMA 23-Dec-2020

The Company has informed that it has credited the Bonus shares for the year ended on June 30, 2020 to the respective shareholders' BO Accounts on December 23, 2020.

BXPHARMA 25-Nov-2020

Trading of the shares of the Company will resume on 26.11.2020 after record date.

BXPHARMA 24-Nov-2020

Trading of the shares of the Company will remain suspended on record date i.e., 25.11.2020.

BXPHARMA 22-Nov-2020

Trading of the shares of the Company will be allowed only in the Spot Market and Block transactions will also be settled as per Spot settlement cycle with cum benefit from 23.11.2020 to 24.11.2020. Trading of the shares of the Company will remain suspended on record date i.e., 25.11.2020.

BXPHARMA 15-Nov-2020

(Q1 Un-audited): Consolidated EPS was Tk. 2.65 for July-September 2020 as against Tk. 2.13 for July-September 2019; Consolidated NOCFPS was Tk. 3.00 for July-September 2020 as against Tk. 4.59 for July-September 2019. NAV per share was Tk. 82.78 as on September 30, 2020 and Tk. 75.09 as on September 30, 2019.

BXPHARMA 04-Nov-2020

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 12, 2020 at 3:30 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended on September 30, 2020.

Previous Next page